下一代抗体治疗药物开发商AAX Biotech获得Trio Impact Invest的投资-动脉网

AAX Biotech secures investment from Trio Impact Invest

D-Pharm 等信源发布 2026-02-20 10:16



可切换为仅中文







Biotech company AAX Biotech announced that Trio Impact Invest AB has invested in AAX Biotech. The investment supports the continued development and scaling of the company’s antibody technology platforms, enabling expanded application areas and strengthened industry collaborations.

生物技术公司AAX Biotech宣布，Trio Impact Invest AB已对AAX Biotech进行投资。这笔投资将支持公司抗体技术平台的持续开发和扩展，拓展应用领域并加强行业合作。

Daniel X Johansson, CEO and CSO of AAX Biotech (left), and Siimon Vaske, CEO of Trio Impact Invest AB (right).

丹尼尔·X·约翰松，AAX生物技术公司首席执行官兼首席科学官（左），西蒙·瓦斯克，Trio Impact Invest AB公司首席执行官（右）。

AAX Biotech AB

AAX生物技术公司

AAX Biotech develops proprietary technologies, including Seqitope® and Opti-mAb®, designed to advance antibody discovery, optimization and developability across modern therapeutic formats. Through these platforms, the company collaborates with partners across antibody discovery and engineering, delivering advanced solutions that enhance antibody performance and support clinical success..

AAX生物技术公司开发了包括Seqitope®和Opti-mAb®在内的专有技术，旨在推动现代治疗形式中的抗体发现、优化和可开发性。通过这些平台，该公司与抗体发现和工程领域的合作伙伴协作，提供增强抗体性能并支持临床成功的先进解决方案。

The investment follows a period of technological and commercial progress at AAX Biotech, including the implementation of advanced automation to enhance platform scalability and several new collaborations, among them one with global pharmaceutical company Daiichi Sankyo.

这项投资是在AAX生物技术公司经历了一段技术和商业进步的时期之后进行的，包括实施先进的自动化以增强平台的可扩展性，以及几项新的合作，其中一项是与全球制药公司第一三共的合作。

Trio Impact Invest’s investment will be allocated to platform advancement and continued development of industry partnerships.

Trio Impact Invest 的投资将用于平台发展和行业合作伙伴关系的持续拓展。

“This investment marks the next phase of platform development and expansion,” said Daniel X Johansson, CEO and CSO of AAX Biotech. “With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners.”.

“这项投资标志着平台开发和扩展的下一阶段，”AAX生物技术公司首席执行官兼首席战略官丹尼尔·X·约翰逊表示。“在Trio Impact Invest的支持下，我们可以扩大我们的专有平台规模，在抗体发现和开发领域扩大其影响，并加强与新老合作伙伴的合作。”

Trio Impact Invest is a Swedish deep tech venture capital firm investing in early-stage, research-intensive companies with the potential for significant societal and commercial impact. Trio Impact Invest focuses on enabling technologies and long-term value creation through active ownership and close collaboration with founders..

Trio Impact Invest是一家瑞典的深度科技风险投资公司，专注于投资具有重大社会和商业影响潜力的早期、研究密集型公司。Trio Impact Invest通过积极的所有权和与创始人的密切合作，专注于赋能技术以及长期价值创造。

“We’re thrilled to make our first investment from Trio Impact Invest in AAX Biotech, backing a team whose enabling technology can meaningfully improve how antibody-based medicines are discovered and optimized,” said Siimon Vaske, CEO of Trio Impact Invest AB. “AAX combines strong scientific capability with a clear roadmap to scale its proprietary platform and drive impact through collaborations and continued technology development.”.

“我们很高兴通过Trio Impact Invest首次投资AAX生物技术公司，支持一个能够显著改善基于抗体药物发现和优化的技术团队，”Trio Impact Invest AB首席执行官Siimon Vaske表示。“AAX结合了强大的科学能力和清晰的扩展路线图，通过合作和持续的技术开发推动其专有平台的影响。”

https://www.bionity.com/en/news/1188128/aax-biotech-secures-investment-from-trio-impact-invest.html

Generative AI antibody design platform

生成式人工智能抗体设计平台

Antiverse raises £3.5M

Antiverse 获得 350 万英镑融资

Read news

阅读新闻